Co-administration of treatment for rifampicin-resistant tuberculosis and chronic hepatitis C virus infection: a TBnet and ESGMYC study

Simone Tunesi, Damien Le Dû, Gina Gualano, Joan-Pau Millet, Aliaksandr Skrahin, Graham Bothamley, Xavier Casas, Delia Goletti, Christoph Lange, Maria Musso, Fabrizio Palmieri, Valérie Pourcher, Christophe Rioux, Alena Skrahina, Nicolas Veziris, Dzmitry Viatushka, Mathilde Jachym-Fréchet, Lorenzo Guglielmetti, for the TBnet, the ESGMYC, the French MDR-TB Group
doi: https://doi.org/10.1101/2021.10.16.21265043

Article Information

doi 
https://doi.org/10.1101/2021.10.16.21265043
History 
  • October 18, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Simone Tunesi1,
  2. Damien Le Dû2,
  3. Gina Gualano3,#,
  4. Joan-Pau Millet4,#,
  5. Aliaksandr Skrahin5,#,
  6. Graham Bothamley6,
  7. Xavier Casas7,
  8. Delia Goletti3,
  9. Christoph Lange8,
  10. Maria Musso3,
  11. Fabrizio Palmieri3,
  12. Valérie Pourcher9,
  13. Christophe Rioux10,
  14. Alena Skrahina5,
  15. Nicolas Veziris11,12,13,
  16. Dzmitry Viatushka5,
  17. Mathilde Jachym-Fréchet2,
  18. Lorenzo Guglielmetti12,13,&,
  19. for the TBnet*,
  20. the ESGMYC**,
  21. the French MDR-TB Group***
  1. 1Infectious Diseases Unit, ASST Valle Olona, Busto Arsizio, Italy
  2. 2Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France
  3. 3National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy
  4. 4Serveis Clínics, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain
  5. 5The Republican Research and Practical Center for Pulmonology and TB, Minsk, Belarus
  6. 6Homerton University Hospital, London E9 6SR, UK; Queen Mary University of London, UK; London School of Hygiene and Tropical Medicine, UK
  7. 7Serveis Clinics, Barcelona, Spain
  8. 8Research Center Borstel, Clinical Infectious Diseases, Borstel, Germany; German Center for Infection Research (DZIF) Tuberculosis Unit, Borstel, Germany; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany; Global TB Program, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA
  9. 9APHP, Service des Maladies Infectieuses et Tropicales, Sorbonne Université, Site Pitié, Paris, France; Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), Inserm UMR_S 1136, Paris, France
  10. 10APHP, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France
  11. 11APHP, Groupe Hospitalier Universitaire Sorbonne Université, site Saint-Antoine, Département de bactériologie, Paris, France
  12. 12APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France
  13. 13Sorbonne Université, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France
  1. ↵&Corresponding author:
    Lorenzo Guglielmetti., Laboratoire de Bactériologie-Hygiène, Faculté de Médecine Sorbonne Université, 91 Boulevard de l’hôpital, 75634 Paris Cedex 13, France; e-mail: lorenzo.guglielmetti{at}aphp.fr; tel: +33 1 40 77 97 56

  1. ↵# The authors contributed equally to this study.

  2. Author contributions: LG and ST made a substantial contribution to the conception and design of the work, to the acquisition, analysis and interpretation of data for the work, performed statistical analysis, wrote the manuscript, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

    DLD and MJF made a substantial contribution to the conception and design of the work, to the acquisition and interpretation of data for the work, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

    GG, JPM, and AS made a contribution to the conception and design of the work, to the acquisition and interpretation of data for the work, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

    All other authors made a substantial contribution to the conception and design of the work, to the acquisition and interpretation of data for the work, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Back to top
Posted October 18, 2021.
Download PDF
Data/Code
Email
Co-administration of treatment for rifampicin-resistant tuberculosis and chronic hepatitis C virus infection: a TBnet and ESGMYC study
Simone Tunesi, Damien Le Dû, Gina Gualano, Joan-Pau Millet, Aliaksandr Skrahin, Graham Bothamley, Xavier Casas, Delia Goletti, Christoph Lange, Maria Musso, Fabrizio Palmieri, Valérie Pourcher, Christophe Rioux, Alena Skrahina, Nicolas Veziris, Dzmitry Viatushka, Mathilde Jachym-Fréchet, Lorenzo Guglielmetti, for the TBnet, the ESGMYC, the French MDR-TB Group
medRxiv 2021.10.16.21265043; doi: https://doi.org/10.1101/2021.10.16.21265043
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area